Phaseline

Companies › BioRestorative Therapies

BioRestorative Therapies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BRTX-100
Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous
–Phase 2Lumbar Disc DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04042844BRTX-100Phase 2Lumbar Disc DiseaseOtherDec 2026

From the company's SEC filings

Cash and short-term investments of $4m on 2026-03-31; operating cash outflow about $16m a year; runway about 3 months at that burn, to Jun 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tego Science Ascendis Pharma Endocrinology Division Eirion Therapeutics Airway Therapeutics Inotrem

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.